This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BCL2A1 / Bcl-2-related protein A1 · Western blot design guide
Design a Western Blot for BCL2A1
Real validated BCL2A1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-BCL2A1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
BCL2A1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~20.1 kDa | |
| Observed band | 30 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | — | |
| Caveat | Observed versus expected mass | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 2 isoform(s) |
Section 1
Real Curated BCL2A1 Western Blot Protocols
The PA2102 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | HELA at 40ug, JURKAT at 40ug Predicted bind size: 30KD Observed bind size: 30KD (catalog PA2102) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | PA2102; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected BCL2A1 Western Blot Band Size?
BCL2A1 is predicted at 20.1 kDa, while antibody QC reports 30 kDa; the cause of this difference is not established.
| Band at 30 kDa | Empirical band reported in whole-cell lysates; confirm its identity with controls |
| Band near 20.1 kDa | Near the predicted mass; identity requires confirmation |
| Multiple discrete bands | Isoforms 1 and 2 are possible contributors, but distinct migration is unestablished |
| Single discrete band | Both isoforms may be unresolved or only one may be detected |
💡Expected BCL2A1 appearanceUniProt predicts 20.1 kDa, while antibody QC reports a 30 kDa band in whole-cell lysates; its identity and the reason for the difference require ordinary band-identity controls.
| UniProt predicted mass | 20.1 kDa is the sequence-based reference, while the reported band is 30 kDa |
| Isoform 1 | Its individual mass and migration are not supplied |
| Isoform 2 | Its individual mass and migration are not supplied |
| Alternative splicing | Isoforms 1 and 2 could differ in size, but their relative migration is unknown |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | The reported 30 kDa band exceeds the 20.1 kDa prediction; the cause is unestablished | Confirm band identity with an independent antibody or BCL2A1 depletion |
| Band lower than expected | Isoform-dependent migration is possible but unverified | Compare with an independent antibody and an isoform-defined control |
| Multiple bands | Isoforms 1 and 2 may contribute, but distinct bands are unproven | Check which bands respond to BCL2A1 depletion |
| No band in lysate | BCL2A1 may be insufficiently expressed or detected in the sample | Use a positive-control lysate and verify loading |
| Weak or no signal | Low abundance or insufficient antibody detection | Check the positive control, loading, and antibody conditions |
Experiment evidence
Western blot images showing BCL2A1 band
PA2102 · BCL2A1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for BCL2A1 Western blot
🧪For positive controls for BCL2A1 in Western blot, you can use a sample with independently confirmed BCL2A1 expression; the supplied HPA data identify no positive tissue or cell.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: BCL2A1 is cytoplasmic, but the supplied HPA data do not establish tissue controls.
HPA tissue expression evidence for BCL2A1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced BCL2A1 Western Blot Tips
Deeper troubleshooting and optimisation questions for BCL2A1, answered from its protein features.
How should BCL2A1 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could BCL2A1 isoforms produce different bands?
Isoforms · UniProt lists two isoforms. In isoform 2, residues 141–175 of the canonical 175-residue sequence are replaced by a shorter segment. Different migration is possible, but this feature alone does not establish where either isoform will appear on a blot.
Choose an epitope outside canonical residues 141–175, which differ in isoform 2. Check the antibody's stated epitope against both sequences; an antibody recognizing the replaced region may miss one isoform. Coordinates here refer to the supplied UniProt canonical sequence.
Use the same defined band region across samples and confirm that the antibody detects the isoform or isoforms being measured. Because isoform 2 changes the canonical C-terminal sequence, an antibody against that region could give misleading comparisons.
Choose an epitope outside canonical residues 141–175, which differ in isoform 2. Check the antibody's stated epitope against both sequences; an antibody recognizing the replaced region may miss one isoform. Coordinates here refer to the supplied UniProt canonical sequence.
Use the same defined band region across samples and confirm that the antibody detects the isoform or isoforms being measured. Because isoform 2 changes the canonical C-terminal sequence, an antibody against that region could give misleading comparisons.
Can annotated modifications explain a BCL2A1 band shift?
PTM · The supplied UniProt features list no modified residues or glycosylation sites. They therefore provide no specific modification to assign to a shifted band. Even a listed modification would not, by itself, establish a visible shift.
Does this guide establish induction of BCL2A1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for BCL2A1 Western blot?
Transfer · Use a transfer setup that retains proteins around the predicted 20.1 kDa mass, and verify recovery with a marker in that range. The supplied features do not establish one transfer method as optimal; also inspect the region around the reported 30 kDa band.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the PA2102 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should BCL2A1 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Why is the BCL2A1 band near 30 kDa instead of 20.1 kDa?
Interpretation · The supplied observed band is 30 kDa, while the predicted mass is 20.1 kDa. These data do not establish the cause of the difference. Confirm band identity with a BCL2A1-specific control before assigning the 30 kDa band.
Compare them with the predicted 20.1 kDa mass and the reported 30 kDa band, then confirm identity with a BCL2A1-specific control. Two isoforms are listed, but their presence alone does not assign an unexpected band to either isoform or explain the reported mass difference.
Compare them with the predicted 20.1 kDa mass and the reported 30 kDa band, then confirm identity with a BCL2A1-specific control. Two isoforms are listed, but their presence alone does not assign an unexpected band to either isoform or explain the reported mass difference.
Boster reagents
BCL2A1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Bcl-2-related protein A1 Bcl2A1 Antibody Picoband®
Cat # PA2102
PA2102 is an anti-BCL2A1 antibody listed for human reactivity. Its Western blot image shows HeLa and Jurkat whole cell lysates, with an observed 30 kDa band matching the predicted size. The supplied evidence covers these tested samples only.
Which to pick: PA2102 is the only listed option. It has a Western blot image for HeLa and Jurkat whole cell lysates at 40 µg per lane, using antibody at 0.5 µg/mL. Choose it when those reported conditions suit your design.
Source: BosterBio BCL2A1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q16548.
- Human Protein Atlas. BCL2A1 tissue expression.
- PMC8469659 — target-verified WB comparison
- PMC13187160 — target-verified WB comparison
- PMC10637801 — target-verified WB comparison